FeesSafety
Pluang+

Candel shares plunge 26% after aglatimagene BLA submission delayed to mid-2027, sparking securities probe

Market News
16 Nov 2026, 23:43 WIB
PRNewsWire
View Source
Bearish
Candel shares plunge 26% after aglatimagene BLA submission delayed to mid-2027, sparking securities probe

Candel Therapeutics' stock dropped over 26% after the company announced a delay in submitting its Biologics License Application (BLA) for aglatimagene in localized prostate cancer from Q4 2026 to mid-2027. The delay, attributed to assay refinements and ongoing FDA discussions, raised concerns about whether Candel had adequately disclosed risks related to the BLA timeline. This has triggered an investigation into potential securities law violations. Investors who bought shares before the announcement and suffered losses may be eligible for compensation.

Candel Therapeutics investigation notice provides context for readers following health-sector stocks. For readers following health-sector stocks, here is Pluang's market snapshot as of Nov 17, 2026 04:12 WIB: out of 150 priced US health-sector stocks, 29 rose and 121 fell. Notable movers include HRTX at USD 0.29 with a -7.54% change and a typical hold time on Pluang of 40 days, ARWR at USD 44.21 with a -7.47% change and a typical hold time of 17 days, and ACB at USD 4.61 with a -6.78% change and 100% sell order activity. The most notable figure is the 121 stocks that fell today in this sector.

More News

Disney Q4 outlook strong with 50%+ EPS growth and streaming as key driver

Disney Q4 outlook strong with 50%+ EPS growth and streaming as key driver

Disney's fiscal Q4 report, due November 17, is expected to show strong growth with analysts forecasting over 50% earnings per share (EPS) growth and more than 12% revenue increase. Streaming revenue rose 11% last quarter with margins hitting double d...

Company Fundamentals
Bullish
3 hours ago
Infoblox launches Australia realm on AWS for local DDI management and security.

Infoblox launches Australia realm on AWS for local DDI management and security.

Infoblox has launched a new Australia realm on Amazon Web Services (AWS) in the Sydney region, providing Australian government agencies and enterprises a local option for managing DNS, DHCP, and IP address management (DDI) with enhanced security. Thi...

Market News
Bullish
3 hours ago
European Commission approves RASONQUE for metastatic pancreatic cancer treatment

European Commission approves RASONQUE for metastatic pancreatic cancer treatment

The European Commission has approved RASONQUE (daraxonrasib), the first broad RAS-targeted oral medicine for adults with metastatic pancreatic adenocarcinoma who have had prior systemic therapy. This approval covers patients with or without identifie...

Market News
Bullish
4 hours ago
SPIE acquires Duflex to boost industrial automation and robotics in the Netherlands.

SPIE acquires Duflex to boost industrial automation and robotics in the Netherlands.

SPIE, a European leader in multi-technical services, has acquired Dutch company Duflex B.V. to enhance its industrial automation, machine building, and robotics capabilities. Duflex, with 26 employees and €8 million revenue in 2025, specializes in ta...

Company Fundamentals
Bullish
5 hours ago
Rexel repurchases 3,878 own shares at an average price of €34.67 from Nov 9-13, 2026

Rexel repurchases 3,878 own shares at an average price of €34.67 from Nov 9-13, 2026

Rexel Développement SAS disclosed that it repurchased a total of 3,878 of its own shares between November 9 and November 13, 2026. The average purchase price during this period was approximately €34.67 per share. This buyback is part of an authorized...

Company Fundamentals
Neutral
5 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App